Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9520)
All Articles published online
|
Publishing Process of This Article
|
May 14, 2017 (publication date) through Jan 30, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Cosme A, Montes M, Ibarra B, Tamayo E, Alonso H, Mendarte U, Lizasoan J, Herreros-Villanueva M, Bujanda L. Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance. World J Gastroenterol 2017; 23(18): 3367-3373 [PMID: 28566898 DOI: 10.3748/wjg.v23.i18.3367] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v23/i18/3367.htm |
| Number | Citing Articles |
| 1 |
Hiroki Tanabe, Keiichi Yoshino, Katsuyoshi Ando, Yoshiki Nomura, Katsuhisa Ohta, Kiichi Satoh, Eiichiro Ichiishi, Akiei Ishizuka, Takaaki Otake, Yutaka Kohgo, Mikihiro Fujiya, Toshikatsu Okumura. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Annals of Clinical Microbiology and Antimicrobials 2018; 17(1) doi: 10.1186/s12941-018-0281-x
|
| 2 |
Neil R. O'Morain, Maria P. Dore, Anthony J. P. O'Connor, Javier P. Gisbert, Colm A. O'Morain. Treatment of Helicobacter pylori infection in 2018. Helicobacter 2018; 23(S1) doi: 10.1111/hel.12519
|
| 3 |
Antonio Moreno-Flores, Carmen Potel-Alvarellos, Maximiliano Álvarez-Fernández. Helicobacter pylori, antimicrobial resistance evolution 2012–2020 in Vigo sanitary area, Pontevedra, Spain. Enfermedades infecciosas y microbiologia clinica (English ed.) 2021; 39(10): 523 doi: 10.1016/j.eimce.2021.09.004
|
| 4 |
Olga P. Nyssen, Marta Espada, Javier P. Gisbert. Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Frontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.913436
|
| 5 |
Takuji Gotoda, Chika Kusano, Sho Suzuki, Toshiki Horii, Ryoji Ichijima, Hisatomo Ikehara. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan. Journal of Gastroenterology 2020; 55(10): 969 doi: 10.1007/s00535-020-01709-4
|
| 6 |
Luis Bujanda, Olga P. Nyssen, Dino Vaira, Ilaria M. Saracino, Giulia Fiorini, Frode Lerang, Sotirios Georgopoulos, Bojan Tepes, Frederic Heluwaert, Antonio Gasbarrini, Theodore Rokkas, Dmitry Bordin, Sinead Smith, Vincent Lamy, María Caldas, Elena Resina, Raquel Muñoz, Ángel Cosme, Ignasi Puig, Francis Megraud, Colm O’Morain, Javier P. Gisbert. Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013–2020: Results of the European Registry on H. pylori Management (Hp-EuReg). Antibiotics 2021; 10(9): 1058 doi: 10.3390/antibiotics10091058
|
| 7 |
Yu Huang, Jinnan Chen, Zhaohui Ding, Xiao Liang, Hong Lu. Susceptibility testing alone will not reliably achieve high Helicobacter pylori cure rates: A systematic review and meta‐analysis. Journal of Gastroenterology and Hepatology 2022; 37(7): 1212 doi: 10.1111/jgh.15864
|
| 8 |
Zishao Zhong, Bingjie Zhan, Baohui Xu, Hengjun Gao. Achieving Helicobacter pylori eradication in the primary treatment requires a deep integration of personalization and standardization. Helicobacter 2022; 27(5) doi: 10.1111/hel.12916
|
| 9 |
Jaikirat Singh Gugnani, Fnu Abhishek, Yash Agarwal, Abhiram Rao Damera , Harkamalpreet Kaur, Bayan Taleb, Rohan Mane, Ujjwal Soni, Kapil D Nayar. Effectiveness of Rifabutin-Based Regimens in Treating Helicobacter pylori Infections. Cureus 2023; doi: 10.7759/cureus.50541
|
| 10 |
Lyudmila Boyanova, Rumyana Markovska, Petyo Hadzhiyski, Nayden Kandilarov, Ivan Mitov.
Rifamycin Use for Treatment of
Helicobacter Pylori
Infection: A Review of Recent Data
. Future Microbiology 2020; 15(12): 1185 doi: 10.2217/fmb-2020-0084
|
| 11 |
Mashiko Setshedi, Stella I. Smith. Helicobacter pylori Infection: Antibiotic Resistance and Solutions for Effective Management in Africa. Antibiotics 2023; 12(6): 969 doi: 10.3390/antibiotics12060969
|
| 12 |
Su Young Kim, Jun-Won Chung. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics 2020; 9(8): 436 doi: 10.3390/antibiotics9080436
|
| 13 |
Tian Geng, Zhong-Su Yu, Xi-Xi Zhou, Bo Liu, Hui-Hua Zhang, Zhong-Yue Li. Antibiotic resistance of Helicobacter pylori isolated from children in Chongqing, China. European Journal of Pediatrics 2022; 181(7): 2715 doi: 10.1007/s00431-022-04456-1
|
| 14 |
Shuai Zhou, Zhengqing Yang, Siqi Zhang, Yuanyuan Gao, Zhenping Tang, Yi Duan, Yalei Zhang, Yayi Wang. Metagenomic insights into the distribution, mobility, and hosts of extracellular antibiotic resistance genes in activated sludge under starvation stress. Water Research 2023; 236: 119953 doi: 10.1016/j.watres.2023.119953
|
| 15 |
Jian Song, Zefeng Huang, Yuanyuan Gao, Weigang Wang, Gang Guo, Yi Duan, Shuai Zhou, Zhenping Tang. Metagenomic insight into the enrichment of antibiotic resistance genes in activated sludge upon exposure to nanoplastics. Environmental Pollution 2024; 363: 125260 doi: 10.1016/j.envpol.2024.125260
|
| 16 |
Elias Xirouchakis, Sotirios D. Georgopoulos. Evaluating treatments with rifabutin and amoxicillin for eradication of Helicobacter pylori infection in adults: a systematic review. Expert Opinion on Pharmacotherapy 2022; 23(2): 201 doi: 10.1080/14656566.2021.1982894
|
| 17 |
Meng-Shu Hsieh, Fu-Chen Kuo, Meng-Chieh Wu, Jiunn-Wei Wang, Chung-Jung Liu, Neng-Sheng Chu, Pei-Yun Tsai, Ping-I Hsu, I-Chen Wu, Jeng-Yih Wu, Deng-Chyang Wu, Fang-Jung Yu, Chao-Hung Kuo. Tailored susceptibility-guided therapy via gastric juice PCR for the first-line H. pylori eradication, a randomized controlled trial. Journal of the Formosan Medical Association 2022; 121(8): 1450 doi: 10.1016/j.jfma.2021.10.011
|
| 18 |
Davide Giuseppe Ribaldone, Sharmila Fagoonee, Marco Astegiano, Marilena Durazzo, Anna Morgando, Tatiana Sprujevnik, Chiara Giordanino, Monica Baronio, Claudio De Angelis, Giorgio Maria Saracco, Rinaldo Pellicano. Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients. Journal of Clinical Medicine 2019; 8(2): 199 doi: 10.3390/jcm8020199
|
| 19 |
Angel Cosme, Silvia Torrente Iranzo, Milagrosa Montes Ros, María Fernández‐Reyes Silvestre, Horacio Alonso Galán, Jacobo Lizasoain, Luis Bujanda. Helicobacter pylori antimicrobial resistance during a 5‐year period (2013‐2017) in northern Spain and its relationship with the eradication therapies. Helicobacter 2019; 24(1) doi: 10.1111/hel.12557
|
| 20 |
Sinéad M. Smith, Colm O’Morain, Deirdre McNamara. Helicobacter pylori resistance to current therapies. Current Opinion in Gastroenterology 2019; 35(1): 6 doi: 10.1097/MOG.0000000000000497
|
| 21 |
Javier P. Gisbert. Rifabutin for the Treatment of Helicobacter pylori Infection: A Review. Pathogens 2020; 10(1): 15 doi: 10.3390/pathogens10010015
|
| 22 |
Sho Suzuki, Mitsuru Esaki, Chika Kusano, Hisatomo Ikehara, Takuji Gotoda. Development of <i>Helicobacter pylori</i> treatment: How do we manage antimicrobial resistance?. World Journal of Gastroenterology 2019; 25(16): 1907-1912 doi: 10.3748/wjg.v25.i16.1907
|
| 23 |
Antonio Moreno-Flores, Carmen Potel-Alvarellos, Maximiliano Álvarez-Fernández. Helicobacter pylori, evolución de la resistencia a antimicrobianos 2012-2020 en el área sanitaria de Vigo, Pontevedra, España. Enfermedades Infecciosas y Microbiología Clínica 2021; 39(10): 523 doi: 10.1016/j.eimc.2020.10.021
|
| 24 |
Cristina Paucar-Carrión, Marcela Espinoza-Monje, Cristian Gutiérrez-Zamorano, Kimberly Sánchez-Alonzo, Romina I. Carvajal, Cristian Rogel-Castillo, Katia Sáez-Carrillo, Apolinaria García-Cancino. Incorporation of Limosilactobacillus fermentum UCO-979C with Anti-Helicobacter pylori and Immunomodulatory Activities in Various Ice Cream Bases. Foods 2022; 11(3): 333 doi: 10.3390/foods11030333
|